Company profile
Impact BioMedical Inc.
AMEX: IBO · Healthcare · Biotechnology
#1102 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
32DFH 39DQ 23GM —SS 22
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, market scale · ↓ workforce scale, net margin
Methodology →Revenue TTM
$35.0k
Rev growth YoY (TTM)
+400.0%
Net income (FY)
-$11.8M
Employees
2
as of 2026-08-23
Market cap
$49.6M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$32.0k$32.0k2025
Net income-$11.8M-$11.8M2025
Operating income-$4.3M-$4.3M2025
Total assets$17.4M$17.4M2025
Liabilities$1.9M$1.9M2025
Equity$12.6M$12.6M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Impact BioMedical Inc.’s revenue?
Impact BioMedical Inc. booked $32.0k in FY2025 revenue, contracting 36% year over year — slower than 78% of Healthcare companies we track, at a -36993.8% net margin.
Peers · Healthcare
Mountain Valley MD Holdings Inc.——Cognetivity Neurosciences Ltd.——CuraScientific Corp——enVVeno Medical Corporation40DBioasis Technologies Inc.——UMC, Inc.——Neighbors
Harris →Key facts
CEOFrank D. Heuszel
SectorHealthcare
IndustryBiotechnology
HeadquartersHouston, TX
ExchangeAMEX: IBO
Employees2
IPO date2024-09-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.